Loading data for HURA — first visit, this takes a few seconds.
TuHURA Biosciences, Inc. (HURA)
NasdaqCM: HURA
· Real-Time Price · USD
2.13
+0.02 (0.95%)
At close: Sep 02, 2026, 10:39 AM
The price, the headline numbers and the latest news, in one place.
TuHURA Biosciences, Inc. (HURA) Stock Price, Analysis & Data
0.95% (1D)
| Bid | 1.6 |
| Market Cap | 129M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -30.6M |
| 0.00 | |
| -0.51 | |
| n/a | |
| -3.36 | |
| P/B (ttm) | 7.10 |
| P/S (ttm) | 0.00 |
| Earnings Date | Nov 13, 2026 |
| Ask | 2.68 |
| Volume | 233,413 |
| Avg. Volume (20D) | 437,503 |
| Open | 2.12 |
| Previous Close | 2.11 |
| Day's Range | 2.08 - 2.23 |
| 52-Week Range | 0.41 - 3.43 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About HURA
TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 22, 2013
Employees 22
Stock Exchange NasdaqCM
Ticker Symbol HURA
Website https://www.tuhurabio.com
Financial Performance
In 2025, TuHURA Biosciences's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -30.05M, an increase of 38.6%.
Financial StatementsEarnings Surprise
TuHURA Biosciences has released their quarterly earnings on Aug 14, 2026:
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -0.14 exceeds estimates by 0.01, with 33.33% YoY growth.
TuHURA Biosciences, Inc. is scheduled to release its earnings on Nov 13, 2026, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
